Business Description
Qualigen Therapeutics Inc
NAICS : 541713
SIC : 8731
ISIN : US74754R2022
Share Class Description:
QLGN: Ordinary SharesDescription
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.27 | |||||
| Equity-to-Asset | -0.93 | |||||
| Debt-to-Equity | -0.67 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.3 | |||||
| 3-Year EPS without NRI Growth Rate | -20.9 | |||||
| 3-Year FCF Growth Rate | -165 | |||||
| 3-Year Book Growth Rate | 38.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.1 | |||||
| 9-Day RSI | 49.44 | |||||
| 14-Day RSI | 43.34 | |||||
| 6-1 Month Momentum % | -62.46 | |||||
| 12-1 Month Momentum % | -85.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.52 | |||||
| Quick Ratio | 0.52 | |||||
| Cash Ratio | 0.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -62.3 | |||||
| Shareholder Yield % | 21.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -385.04 | |||||
| ROIC % | -257.82 | |||||
| ROC (Joel Greenblatt) % | -358.14 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.66 | |||||
| EV-to-EBITDA | -0.66 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | -0.46 | |||||
| Earnings Yield (Greenblatt) % | -151.52 | |||||
| FCF Yield % | -286.21 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QLGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qualigen Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -285.848 | ||
| Beta | -0.02 | ||
| Volatility % | 62.04 | ||
| 14-Day RSI | 43.34 | ||
| 14-Day ATR ($) | 0.709561 | ||
| 20-Day SMA ($) | 4.409695 | ||
| 12-1 Month Momentum % | -85.23 | ||
| 52-Week Range ($) | 3.3358 - 37.45 | ||
| Shares Outstanding (Mil) | 0.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qualigen Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Qualigen Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Qualigen Therapeutics Inc Frequently Asked Questions
What is Qualigen Therapeutics Inc(QLGN)'s stock price today?
The current price of QLGN is $4.62. The 52 week high of QLGN is $37.45 and 52 week low is $3.34.
When is next earnings date of Qualigen Therapeutics Inc(QLGN)?
The next earnings date of Qualigen Therapeutics Inc(QLGN) is 2025-02-14 Est..
Does Qualigen Therapeutics Inc(QLGN) pay dividends? If so, how much?
Qualigen Therapeutics Inc(QLGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers